Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “mTOR Protein”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 17 of 0 results

Not applicableLooking for participantsNCT05235464
What this trial is testing

High Protein Diet and Atherosclerosis

Who this might be right for
Atherosclerosis
University of Missouri-Columbia 24
Not applicableLooking for participantsNCT07121010
What this trial is testing

How Animal and Plant Protein Shakes Change the Body's Nutrient and Health Responses

Who this might be right for
Cardiometabolic Health
University of Pittsburgh 20
Testing effectiveness (Phase 2)Study completedNCT01467986
What this trial is testing

Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma

Who this might be right for
Neuroblastoma Recurrent
University of Regensburg 130
Early research (Phase 1)Study completedNCT01353625
What this trial is testing

Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.

Who this might be right for
Glioblastoma MultiformeSquamous Cell Carcinoma of Head and NeckProstate Cancer+3 more
Celgene 118
Not applicableEnded earlyNCT03946774
What this trial is testing

Dietary Protein and Monocyte/Macrophage Mammalian Target of Rapamycin (mTOR) Signaling

Who this might be right for
Dietary Protein
Washington University School of Medicine 21
Early research (Phase 1)Study completedNCT01854606
What this trial is testing

Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma

Who this might be right for
CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma
Novartis Pharmaceuticals 31
Early research (Phase 1)Study completedNCT00973076
What this trial is testing

Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055

Who this might be right for
CancerSolid TumorsAdvanced Solid Malignancies
AstraZeneca 19
Early research (Phase 1)WithdrawnNCT01194193
What this trial is testing

Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours

Who this might be right for
CancerAdvanced Solid TumoursLymphomas
AstraZeneca 63
Not applicableLooking for participantsNCT05233722
What this trial is testing

MTOR as Mediator of Insulin Sensitivity Study

Who this might be right for
Insulin Sensitivity
University of Copenhagen 10
Not applicableUnknownNCT04112537
What this trial is testing

Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship

Who this might be right for
Tuberous Sclerosis Complex
University Hospital, Montpellier 90
Early research (Phase 1)Study completedNCT00962507
What this trial is testing

Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Who this might be right for
LymphomaMultiple Myeloma and Plasma Cell Neoplasm
City of Hope Medical Center 11
Early research (Phase 1)Study completedNCT02238496
What this trial is testing

Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas

Who this might be right for
Brain Tumor, RecurrentGlioblastomaAnaplastic Astrocytoma+2 more
Andrew B Lassman, MD 10
Testing effectiveness (Phase 2)Study completedNCT00353301
What this trial is testing

Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma

Who this might be right for
Renal Cell Carcinoma
University of Colorado, Denver 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT06385496
What this trial is testing

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Study completedNCT02596828
What this trial is testing

Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma

Who this might be right for
Pineoblastoma
University of Regensburg 4
Testing effectiveness (Phase 2)Study completedNCT01177397
What this trial is testing

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

Who this might be right for
Multiple MyelomaDiffuse Large B-Cell LymphomaGlioblastoma Multiforme+4 more
Celgene 226
Early research (Phase 1)Study completedNCT00999882
What this trial is testing

Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients

Who this might be right for
CancerAdvanced Hepatocellular Carcinoma
AstraZeneca 26